Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses: 2021-2025

Historic Accumulated Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $30.9 million.

  • Kiniksa Pharmaceuticals International's Accumulated Expenses fell 23.37% to $30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year decrease of 23.37%. This contributed to the annual value of $32.4 million for FY2024, which is 16.69% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Accumulated Expenses stood at $30.9 million, which was down 13.95% from $36.0 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Accumulated Expenses high stood at $44.7 million for Q1 2024, and its period low was $20.9 million during Q1 2023.
  • Its 3-year average for Accumulated Expenses is $33.2 million, with a median of $33.4 million in 2024.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Accumulated Expenses surged by 114.12% in 2024 and then plummeted by 50.52% in 2025.
  • Kiniksa Pharmaceuticals International's Accumulated Expenses (MRQ) stood at $38.0 million in 2021, then dropped by 20.82% to $30.1 million in 2022, then fell by 7.92% to $27.7 million in 2023, then increased by 16.69% to $32.4 million in 2024, then fell by 4.37% to $30.9 million in 2025.
  • Its Accumulated Expenses stands at $30.9 million for Q3 2025, versus $36.0 million for Q2 2025 and $22.1 million for Q1 2025.